Biomendics’ BM-3103, formulated as TolaSure Gel for epidermolysis bullosa simplex (EBS), has been granted fast track status by the U.S. Food and Drug Administration (FDA) for treating people with fragile skin due to EBS. The new designation could accelerate the development and review of the topical treatment if the gel…
Discussion
Health Canada has granted priority review to Chiesi Global Rare Diseases’ application seeking approval of Filsuvez (birch triterpenes), a topical gel to treat skin wounds in people with dystrophic epidermolysis bullosa (DEB) or junctional epidermolysis bullosa (JEB), ages 6 months or older. Priority review is granted to therapies for…
Discussion
“We need to put sunscreen on you,” I said again to Jonah, my (sometimes stubborn) teenager who lives with epidermolysis bullosa (EB), as he stood out in the sun because he was shivering under the shade of the Shibumi. As Jonah ages and his skin doesn’t blister quite as…
Becoming educated and informed about epidermolysis bullosa is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your EB journey.
There is no cure for EB yet, but there are treatments that can help manage the disease. Learn more about the approved and experimental therapies here.
Get regular updates to your inbox.
